Medical Marijuana Inc (OTCMKTS:MJNA): What's Important And What's Not

Medical Marijuana Inc (OTCMKTS:MJNA) is a cannabis play that we keep coming back to. The company has staged a number of upside runs across the last few months, but unlike many other entities in the space, has managed to maintain a large portion of its legalization ballot induced gains this year.As we have touched on on in the past, sustainability of this company's valuation is rooted in its positive news flow. Every week or so, the company puts out two or three fresh press releases, detailing operational updates. Some, of course, are less pertinent than others. However, there is a balance to be struck in this type of market, and for a company of this sort of size, striking said balance ensures there are enough pertinent releases to stop investors writing off all of your releases as fluff.Medical Marijuana looks to have struck this balance nicely, and as such, remains in play for us as a potential runner for the remainder of the first quarter and beyond. A couple of fresh releases put out this and last week should serve to support some near-term upside momentum, so, ahead of markets responding to the news, here is what is important (and what is not) from the most recent reports.As far as we see it, there are two recent updates worth mentioning and one we will put into the latter category of non-importance. The first of note is the acceptance of an individual for treatment with one of the company's assets in Brazil. The individual in question is an Alzheimer's sufferer, and towards the end of last year, the possibility of said patient being treated with Medical Marijuana's Real Scientific Hemp Oil (RSHO) was a hot topic in the sector. This isn’t an approved pharmaceutical in this indication, of course, but the interest was rooted in the fact that if the company can get a green light from the Brazilian medical authorities for this one off novel approach, it could pave the way for a clinical development efforts at best, and bring some interesting news and data home for the company at worst. Well, Medical Marijuana just got the green light, and the patient is now receiving RSHO. For us, that's a big development, and one that will likely draw plenty of speculative volume towards the company near term.The second update of note is the announcing of an affiliate program that will underpin an aggressive marketing strategy for one of the company's subsidiary's product portfolios. The subsidiary is called HempMeds, and the product portfolio is a range of hemp-based topical formulations designed to improve skin quality, reduce aging effects, moisturize, that sort of thing. Affiliate marketing is one of the best ways to get a product in the hands of consumers these days, and many of the companies with which HempMeds is competing have similar programs in place. With a 15% commission on referred sales, HempMeds is positioned competitively, and should attract the attention of affiliate marketers in the sector relatively easily. This strategy plays into a quantitative catalyst, with the next earnings report likely set to offer some degree of insight into the efficacy of the affiliate execution, and its implications for top and bottom line moving forward.So that is the important news, but let's close this out on the company's latest release; the announcement that one of its subsidiaries (Kannaway) is hosting a red carpet event for its network of retailers and distributors. As we said earlier, this company tends to put out a few fluff releases, and this is very much one of them. So long as it can support these sorts of releases with actual developments (such as the two discussed above), however, then they have the potential to serve up a little bit of interest boost as a bridge between pertinent advances.We will be updating our subscribers as soon as we know more. For the latest updates on MJNA, sign up below!Disclosure: We have no position in MJNA and have not been compensated for this article.